

## Addendum

**Addendum: Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss****Maroun Bou Zerdan<sup>1</sup>, Prashanth Ashok Kumar<sup>2</sup>, Elio Haroun<sup>3</sup>, Nimisha Srivastava<sup>2</sup>, Jeffrey Ross<sup>4,5</sup> and Abirami Sivapiragasam<sup>2</sup>**<sup>1</sup>Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY 13210, USA<sup>2</sup>Department of Internal Medicine, Division of Hematology Oncology, SUNY Upstate Medical University, Syracuse, NY 13210, USA<sup>3</sup>SUNY Upstate Medical University, Syracuse, NY 13210, USA<sup>4</sup>Foundation Medicine, Inc., Morrisville, NC 27560, USA<sup>5</sup>Departments of Pathology and Urology, SUNY Upstate Medical University, Syracuse, NY 13210, USA**Published:** August 07, 2023**Copyright:** © 2023 Bou Zerdan et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.**This article has an addendum:** No external funding was provided for this research.Original article: Oncotarget. 2023; 14:178–187. <https://doi.org/10.18632/oncotarget.28376>